68Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients
Loading...
Date
Authors
Sathekge, Mike Machaba
Lengana, Thabo
Modiselle, Moshe
Vorster, Mariza
Zeevaart, Jan Rijn
Maes, Alex
Ebenhan, Thomas
Van de Wiele, Christophe
Journal Title
Journal ISSN
Volume Title
Publisher
Springer
Abstract
BACKGROUND : To report on imaging findings using 68Ga-PSMAHBED-
CC PET in a series of 19 breast carcinoma patients.
METHODS : 68Ga-PSMA-HBED-CC PET imaging results obtained
were compared to routinely performed staging examinations
and analyzed as to lesion location and progesterone
receptor status.
RESULTS : Out of 81 tumor lesions identified, 84% were identified
on 68Ga-PSMA-HBED-CC PET. 68Ga-PSMA-HBED-CC
SUVmean values of distant metastases proved significantly
higher (mean, 6.86, SD, 5.68) when compared to those of primary
or local recurrences (mean, 2.45, SD, 2.55, p = 0.04) or
involved lymph nodes (mean, 3.18, SD, 1.79, p = 0.011).
SUVmean values of progesterone receptor-positive lesions
proved not significantly different from progesterone receptornegative
lesions. SUV values derived from FDG PET/CT, available
in seven patients, and 68Ga-PSMA-HBED-CC PET/CT
imaging proved weakly correlated (r = 0.407, p= 0.015).
CONCLUSIONS : 68Ga-PSMA-HBED-CC PET/CT imaging in
breast carcinoma confirms the reported considerable variation
of PSMA expression on human solid tumors using
immunohistochemistry.
Description
Keywords
68Ga-PSMA, PET/CT, Breast cancer, Prostate-specific membrane antigen (PSMA), Positron emission tomography (PET)
Sustainable Development Goals
Citation
Sathekge, M., Lengana, T., Modiselle, M. et al. 68Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients. European Journal of Nuclear Medicine and Molecular Imaging (2017) 44: 689-694. https://doi.org/10.1007/s00259-016-3563-6.